资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：疫苗、高血压防治、中 药、送转填权、创新药等。 8月26日，一品红盘中下跌2.01%，截至09:44，报68.11元/股，成交2.28亿元，换手率0.78%，总市值 307.65亿元。 资金流向方面，主力资金净流入746.74万元，特大单买入2341.30万元，占比10.28%，卖出2045.18万 元，占比8.98%；大单买入3744.18万元，占比16.45%，卖出3293.57万元，占比14.47%。 一品红今年以来股价涨299.24%，近5个交易日跌4.79%，近20日跌8.85%，近60日涨31.41%。 今年以来一品红已经5次登上龙虎榜，最近一次登上龙虎榜为7月21日，当日龙虎榜净买入6557.61万 元；买入总计3.05 ...

截至发稿，马毅累计任职时间11年159天，现任基金资产总规模60.63亿元，任职期间最佳基金回报 44.58%， 任职期间最差基金回报-0.61%。 从基金十大重仓股角度 数据显示，同泰基金旗下1只基金重仓一品红。同泰大健康主题混合A（011002）二季度减持1.91万股， 持有股数2.69万股，占基金净值比例为5.99%，位居第二大重仓股。根据测算，今日浮亏损失约9.41万 元。 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模618.23万。今年以来收益51.96%， 同类排名304/8192；近一年收益60.49%，同类排名1079/7956；成立以来亏损37.65%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 8月22日，一品红跌5.02%，截至发稿，报66.22元/股，成交3.66亿元，换手率1.30%，总市值299.11亿 元。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销 ...

Core Viewpoint - The company is undergoing a transformation phase in 2024, facing challenges in its core business areas while focusing on innovative drug development to counteract revenue declines [1][2]. Financial Performance - In 2024, the company reported an operating revenue of 1.45 billion yuan and a net loss attributable to shareholders of 540 million yuan [1]. - For Q1 2025, the company achieved an operating revenue of 377 million yuan, with a net profit of approximately 56.59 million yuan [1][3]. Business Challenges - The company experienced significant revenue declines in its core business segments, with children's medicine revenue dropping by 39.04% to 936 million yuan and chronic disease medication revenue decreasing by 51.97% to 370 million yuan [2]. - Despite an increase in overall product shipment volume, revenue fell due to declining product prices, impacting the company's operational performance [2]. Research and Development - The company has 71 projects in the pipeline, including 15 innovative drug projects, and has increased its R&D investment to 325 million yuan, accounting for 22.4% of its operating revenue [2]. - The company holds 193 drug registration approvals, with 82 under national medical insurance and 26 under national essential drug lists [2]. Key Product Development - The AR882 capsule, a new generation targeted URAT1 inhibitor for treating hyperuricemia and gout, has entered Phase III clinical trials, with the first patient enrolled in March 2024 [4][5]. - The drug has received Fast Track Designation from the FDA for treating visible gout stones in clinical patients [5]. Market Context - The prevalence of hyperuricemia in China is approximately 13.3%, affecting around 177 million people, with gout affecting 1.1% of the population [4].